Nasus Pharma (NSRX) Cash & Equivalents (2024 - 2025)
Nasus Pharma (NSRX) reported Cash & Equivalents of $1.2 million for Q4 2025, up 335.56% on a YoY basis from $284000.0 in Q4 2024, and up 433.19% quarter-over-quarter from $232000.0 in Q2 2025.
Nasus Pharma (NSRX) Cash & Equivalents (2024 - 2025) Analysis & Trends
Nasus Pharma has reported Cash & Equivalents for 2 years, with the latest figure at $1.2 million in Q4 2025.
- For the quarter ending Q4 2025, Cash & Equivalents rose 335.56% year-over-year to $1.2 million; the trailing twelve-month figure through Dec 2025 stood at $1.2 million (up 335.56% YoY), and the FY2025 full-year result was $1.2 million, up 335.56% from the prior year.
- Cash & Equivalents for Q4 2025 stood at $1.2 million, up from $232000.0 in the prior quarter.
- The five-year high for Cash & Equivalents was $1.2 million in Q4 2025, with the low at $232000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 4.64 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 5.28 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 21.69 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 9.39 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 5.33 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 7.63 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 1.70 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 9.57 Bn |
| 10 | Nasus Pharma | 24.83 Mn | 20.55 Mn | - | 1.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.24 Mn |
| Jun 30, 2025 | 232,000.00 |
| Dec 31, 2024 | 284,000.00 |